GlycoMimetics, Inc. (GLYC) Thursday said the Phase 1a study of its drug candidate GMI-1687 met its primary goal.
In the Phase 1a study, healthy volunteers were randomized to receive either GMI-1687 or placebo. The study met its primary and secondary endpoints of safety, tolerability and pharmacokinetics. Further, there were no dose limiting toxicities or safety signals.
GMI-1687 is being developed for the treatment of inflammatory diseases, with initial focus on sickle cell disease (SCD), the most common inherited blood disorder in the United States.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.